Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Authors
Paul Takam Kamga (ORCID: https://orcid.org/0000-0002-8586-1381)
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Paul Takam Kamga, Elvire Pons‐Tostivint, Etienne Giroux‐Leprieur, Adrien Costantini et al.
Citations
2 citations
Journal
Cancer Immunology Immunotherapy
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
2.09
article
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Ambroise-Paré (FR), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (FR), Nantes Université (FR)